Compare RICK & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RICK | IKT |
|---|---|---|
| Founded | 1983 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.7M | 220.5M |
| IPO Year | 1996 | 2020 |
| Metric | RICK | IKT |
|---|---|---|
| Price | $25.88 | $2.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 25.6K | ★ 1.0M |
| Earning Date | 05-08-2026 | 03-26-2026 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | ★ 272.73 | 57.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $144,896,000.00 | N/A |
| Revenue This Year | $19.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.76 | $1.33 |
| 52 Week High | $38.25 | $2.53 |
| Indicator | RICK | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 50.51 | 59.05 |
| Support Level | $25.08 | $1.63 |
| Resistance Level | $26.80 | $2.31 |
| Average True Range (ATR) | 0.72 | 0.16 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 62.92 | 46.67 |
RCI Hospitality Holdings Inc through its subsidiaries, owns and operates establishments that offer live adult entertainment, restaurant, and or bar operations. It also owns and operates a communication company serving the adult nightclub industry. The company's operating business segments are Nightclubs, Bombshells, and Others. It operates nightclubs through the following brands Rick's Cabaret, Vivid Cabaret, Tootsie's Cabaret, Club Onyx, and Jaguars Club. In the Bombshells segment, the company is building a chain of Restaurants and Sports Bars in Dallas, Austin, and Houston, Texas. It derives the majority of revenue from the Nightclubs segment that engages in the sale of alcoholic beverages, food, and merchandise items; service in the form of cover charges, and room rentals.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.